김선영 교수 연구실
article|
hybrid
·인용수 1
·2025
Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials
Damien Yeo, Yong Suk Jo, Jin Young Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon
Diabetes Obesity and Metabolism
초록
In this study, GLP-1RAs were associated with cardiovascular, renal, and metabolic benefits in type 2 diabetes without increasing cancer risk, though gastrointestinal adverse events were common. Our findings support the clinical use of GLP-1RAs, with attention to individual risk profiles and treatment tolerability.
키워드
Type 2 diabetesAdverse effectClinical trialGlucagon-like peptide 1 receptorRandomized controlled trialGlucagon-like peptide-1ReceptorMEDLINE